Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial

European urology oncology - Tập 5 Số 5 - Trang 519-525 - 2022
Bo Dai1, Sheng Zhang2, Fangning Wan3, Hongkai Wang3, Junyu Zhang3, Qifeng Wang4, Min Ren4, Xue-Jun Ma5, Miao Mo6, Yao Zhu3, Xiaojian Qin3, Guowen Lin3, Dingwei Ye7
1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China; Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China; Fudan University Prostate Cancer Institute, Shanghai, People's Republic of China. Electronic address: [email protected].
2Department of Oncology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China; Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China; Fudan University Prostate Cancer Institute, Shanghai, People's Republic of China; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
3Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China; Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China; Fudan University Prostate Cancer Institute, Shanghai, People's Republic of China.
4Department of Oncology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China; Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China; Fudan University Prostate Cancer Institute, Shanghai, People's Republic of China; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
5Department of Oncology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China; Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China; Fudan University Prostate Cancer Institute, Shanghai, People's Republic of China; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
6Department of Oncology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China; Clinical Statistical Center, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
7Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Fudan University Shanghai Medical College, Shanghai, People's Republic of China; Shanghai Genitourinary Cancer Institute, Shanghai, People's Republic of China; Fudan University Prostate Cancer Institute, Shanghai, People's Republic of China. Electronic address: [email protected].

Tóm tắt

Từ khóa


Tài liệu tham khảo

Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012

Fossati, 2015, Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study, Eur Urol, 67, 3, 10.1016/j.eururo.2014.08.056

Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry, Eur Urol, 66, 602, 10.1016/j.eururo.2014.04.009

Rusthoven, 2016, Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer, J Clin Oncol, 34, 2835, 10.1200/JCO.2016.67.4788

Satkunasivam, 2015, Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis, J Urol, 194, 378, 10.1016/j.juro.2015.02.084

Boeve, 2019, Eur Urol, 75, 410, 10.1016/j.eururo.2018.09.008

Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657

Sooriakumaran, 2016, A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation, Eur Urol, 69, 788, 10.1016/j.eururo.2015.05.023

Yao, 2013, Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer, Asian J Androl, 15, 241, 10.1038/aja.2012.120

Sweeney, 2015, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N Engl J Med, 377, 338, 10.1056/NEJMoa1702900

Hoyle, 2019, Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer, Eur Urol, 76, 719, 10.1016/j.eururo.2019.08.006

Davis, 2019, Enzalutamide with standard first-line therapy in metastatic prostate cancer, N Engl J Med, 381, 121, 10.1056/NEJMoa1903835

Chi, 2019, Apalutamide for metastatic, castration-sensitive prostate cancer, N Engl J Med, 381, 13, 10.1056/NEJMoa1903307

Thông tin
Thông tin xuất bản

European urology oncology

Tập 5 Số 5

519-525

Thông tin tác giả